HSDT
ANALYST COVERAGE3 analysts
BUY
Buy
267%
Hold
133%
2 Buy (67%)1 Hold (33%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$135.07M
Revenue TTM$9.59M
Net Income TTM-$136.85M
Free Cash Flow-$17.81M
Gross Margin94.2%
Operating Margin-196.6%
Net Margin-1427.1%
Return on Equity-155.3%
Return on Assets-68.2%
Debt / Equity0.00
Current Ratio9.90
EPS TTM$-1.78
PRICE
Prev Close
2.31
Open
2.32
Day Range2.26 – 2.34
2.26
2.34
52W Range1.59 – 227.10
1.59
227.10
0% of range
VOLUME & SIZE
Avg Volume
368.0K
FUNDAMENTALS
P/E Ratio
0.0x
Value territory
EPS (TTM)
Div Yield
No dividend
Beta
1.11
Market-like
TECHNICAL
RSI (14)
51
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19

HSDT News

About

helius medical technologies, inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. the company's product is portable neuromodulation stimulator (pons), a medical device in canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. its pons device treats neurostimulation of cranial nerves via the tongue to restore lost function. the company is headquartered in newtown, pennsylvania.

Industry
Surgical and Medical Instrument Manufacturing
CEO
Philippe Deschamps
Agustina Gani TjandrasuwitaCOO & Deputy CFO
Antonella Favit-Van PeltChief Medical Officer
Choon Wee CheeExecutive Chairman
Dane Carl AndreeffPresident, Chief Executive Officer & Director
Jeffrey S. MathiesenChief Financial Officer, Treasurer & Secretary
Lawrence PiccianoSenior Vice President of Engineering, Quality & Regulatory Affairs